UP!
|
Type
|
Public (NASDAQ: NUVA) |
|---|---|
| Industry | Medical Technology |
| Founded | 1997 |
| Headquarters | San Diego, California |
|
Key people
|
Alexis Lukianov (Chairman and CEO) |
| Products | Medical Devices |
| Revenue | $619 million (2012) |
| Website | http://www.nuvasive.com/ |
NuVasive, Inc., based in San Diego, California, is a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders. NuVasive is a publicly traded company and is listed on the NASDAQ under the symbol NUVA.
NuVasive’s product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as a growing offering of cervical and motion preservation products.
MAS combines three categories of NuVasive’s current product offerings: NeuroVision, a proprietary software-driven nerve avoidance system; MaXcess, a unique split-blade design retraction system; and specialized implants. The MAS platform enables procedures such as XLIF, or eXtreme Lateral Interbody Fusion, a minimally disruptive spine surgery that accesses the spine through the patient’s side. This procedure is a more modern surgical option for treatment of scoliosis than the Harrington Rod, which is no longer used.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-11-07 | Future report Set alerts | |
| Q2 2022 | 2022-08-03 | 0.47 | 0.47 |
| Q1 2022 | 2022-05-04 | 0.00 | 0.00 |
| Q4 2021 | 2022-02-23 | 0.40 | 0.40 |
| Q3 2021 | 2021-11-09 | 0.32 | 0.32 |
| Q2 2021 | 2021-07-28 | 0.60 | 0.60 |
| Q1 2021 | 2021-05-05 | 0.37 | 0.37 |
| Q4 2020 | 2021-02-25 | 0.00 | 0.00 |
| Q3 2020 | 2020-10-29 | 0.00 | 0.00 |
| Q2 2020 | 2020-08-04 | -0.40 | -0.98 |
| 2016-07-13 | Upgrade | JPMorgan Chase & Co. | Neutral to Overweight | $55.00 to $74.00 |
| 2016-06-07 | Reiterated Rating | Morgan Stanley | Hold | $57.00 |
| 2016-06-07 | Reiterated Rating | Brean Capital | Buy | $58.00 to $60.00 |
| 2016-06-06 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2016-06-03 | Reiterated Rating | Piper Jaffray | Overweight | $58.00 |
| 2016-06-03 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $58.00 |
| 2016-05-27 | Upgrade | Barclays | Equal Weight to Overweight | $58.00 to $63.00 |
| 2016-05-27 | Upgrade | Barclays PLC | Equal Weight to Overweight | $58.00 to $63.00 |
| 2016-05-10 | Reiterated Rating | Leerink Swann | Buy | $65.00 |
| 2016-04-27 | Reiterated Rating | Piper Jaffray | Buy | $50.00 to $58.00 |
| 2016-04-27 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2016-04-27 | Reiterated Rating | Morgan Stanley | Hold | |
| 2016-04-27 | Reiterated Rating | Needham & Company LLC | Hold | |
| 2016-04-27 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-04-27 | Reiterated Rating | Cowen and Company | Buy | $52.00 to $63.00 |
| 2016-03-17 | Reiterated Rating | Leerink Swann | Outperform | |
| 2016-02-12 | Reiterated Rating | Piper Jaffray | Overweight | $59.00 to $50.00 |
| 2016-01-12 | Reiterated Rating | Canaccord Genuity | Buy | $59.00 |
| 2016-01-07 | Reiterated Rating | Needham & Company LLC | Hold | |
| 2016-01-07 | Reiterated Rating | Leerink Swann | Outperform | $63.00 |
| 2016-01-06 | Reiterated Rating | Canaccord Genuity | Buy | $59.00 |
| 2015-12-14 | Boost Price Target | Leerink Swann | Outperform | $60.00 to $63.00 |
| 2015-12-13 | Reiterated Rating | Needham & Company LLC | Hold | |
| 2015-12-11 | Reiterated Rating | Cowen and Company | Outperform | $60.00 to $65.00 |
| 2015-12-11 | Reiterated Rating | Canaccord Genuity | Buy | $58.00 to $59.00 |
| 2015-12-11 | Upgrade | Bank of America | Underperform to Neutral | $56.00 |
| 2015-12-11 | Upgrade | Bank of America Corp. | Underperform to Neutral | $56.00 |
| 2015-10-29 | Reiterated Rating | Needham & Company LLC | Hold | |
| 2015-10-29 | Reiterated Rating | Canaccord Genuity | Buy | $58.00 |
| 2015-10-28 | Reiterated Rating | Leerink Swann | Outperform | $65.00 to $60.00 |
| 2015-10-28 | Boost Price Target | Brean Capital | Buy | $56.00 to $58.00 |
| 2015-10-15 | Reiterated Rating | Morgan Stanley | Equal Weight | $60.00 |
| 2015-10-06 | Upgrade | BMO Capital Markets | Market Perform to Outperform | $52.00 to $64.00 |
| 2015-10-06 | Upgrade | Canaccord Genuity | Hold to Buy | $52.00 to $58.00 |
| 2015-10-05 | Reiterated Rating | RBC Capital | Outperform | $58.00 |
| 2015-10-05 | Reiterated Rating | Royal Bank Of Canada | Outperform | $58.00 |
| 2015-09-14 | Initiated Coverage | Morgan Stanley | Equal to Equal Weight | $60.00 |
| 2015-09-01 | Reiterated Rating | Leerink Swann | Buy | |
| 2015-07-30 | Reiterated Rating | Canaccord Genuity | Hold | $52.00 |
| 2015-07-29 | Reiterated Rating | Leerink Swann | Outperform | $57.00 to $65.00 |
| 2015-07-29 | Boost Price Target | Barclays | Equal Weight | $54.00 to $56.00 |
| 2015-07-29 | Reiterated Rating | RBC Capital | Outperform | $58.00 |
| 2015-07-29 | Upgrade | Northland Securities | Market Perform to Outperform | $48.00 to $68.00 |
| 2015-07-27 | Reiterated Rating | Brean Capital | Buy | $55.00 to $56.00 |
| 2015-06-26 | Boost Price Target | RBC Capital | $56.00 to $58.00 | |
| 2015-06-12 | Reiterated Rating | Piper Jaffray | Overweight | $56.00 |
| 2015-06-03 | Downgrade | Goldman Sachs | Buy to Neutral | $52.00 |
| 2015-06-03 | Downgrade | Goldman Sachs Group Inc. | Buy to Neutral | $52.00 |
| 2015-05-14 | Initiated Coverage | Northland Securities | Market Perform | $46.00 |
| 2015-05-09 | Reiterated Rating | BMO Capital Markets | Market Perform | $50.00 to $52.00 |
| 2015-05-05 | Set Price Target | Brean Capital | Buy | $55.00 |
| 2015-04-30 | Reiterated Rating | Canaccord Genuity | Hold | $49.00 |
| 2015-04-15 | Downgrade | Canaccord Genuity | Buy to Hold | $54.00 to $49.00 |
| 2015-04-02 | Downgrade | Bank of America | Neutral to Underperform | $49.00 |
| 2015-04-01 | Set Price Target | Leerink Swann | Buy | $57.00 |
| 2015-04-01 | Set Price Target | Canaccord Genuity | Buy | $54.00 |
| 2015-02-25 | Reiterated Rating | Canaccord Genuity | Buy | $54.00 |
| 2015-02-25 | Boost Price Target | Brean Capital | Buy | $53.00 to $55.00 |
| 2015-01-26 | Set Price Target | Canaccord Genuity | Buy | $51.00 |
| 2015-01-13 | Set Price Target | Brean Capital | Buy | $53.00 |
| 2015-01-13 | Boost Price Target | WallachBeth Capital | Buy | $49.00 to $55.00 |
| 2015-01-13 | Boost Price Target | Robert W. Baird | Outperform | $50.00 to $55.00 |
| 2015-01-13 | Downgrade | Summer Street | Buy to Neutral | |
| 2015-01-08 | Upgrade | RBC Capital | Sector Perform to Outperform | $45.00 to $56.00 |
| 2015-01-07 | Initiated Coverage | Piper Jaffray | Overweight | $51.00 to $56.00 |
| 2015-01-05 | Boost Price Target | Jefferies Group | Buy | $48.00 to $63.00 |
| 2014-12-04 | Boost Price Target | Brean Capital | Buy | $44.00 to $53.00 |
| 2014-11-17 | Upgrade | Wells Fargo & Co. | Market Perform to Outperform | |
| 2014-11-17 | Upgrade | Wells Fargo | Market Perform to Outperform | |
| 2014-11-14 | Boost Price Target | Barclays | Equal Weight | $44.00 to $48.00 |
| 2014-11-11 | Upgrade | Cowen and Company | Market Perform to Outperform | $44.00 to $51.00 |
| 2014-10-31 | Reiterated Rating | Barclays | Equal Weight | $42.00 to $44.00 |
| 2014-10-31 | Reiterated Rating | Canaccord Genuity | Buy | $48.00 to $49.00 |
| 2014-09-30 | Upgrade | Brean Capital | Hold to Buy | $44.00 |
| 2014-07-30 | Reiterated Rating | Jefferies Group | Buy | $45.00 to $48.00 |
| 2014-07-30 | Reiterated Rating | Barclays | Equal Weight | $40.00 to $42.00 |
| 2014-06-25 | Upgrade | Goldman Sachs | Neutral to Buy | |
| 2014-05-21 | Downgrade | Needham & Company LLC | Buy to Hold | $40.00 |
| 2014-04-30 | Lower Price Target | Canaccord Genuity | Buy | $51.00 to $48.00 |
| 2014-04-30 | Upgrade | Summer Street | Neutral to Buy | $42.00 |
| 2014-04-30 | Boost Price Target | RBC Capital | Sector Perform | $35.00 to $39.00 |
| 2014-03-04 | Boost Price Target | JPMorgan Chase & Co. | Neutral | $34.00 to $40.00 |
| 2014-03-04 | Boost Price Target | Jefferies Group | $35.00 to $45.00 | |
| 2014-03-04 | Boost Price Target | BMO Capital Markets | $30.00 to $38.00 | |
| 2014-03-04 | Boost Price Target | Piper Jaffray | Overweight | $43.00 to $44.00 |
| 2014-01-22 | Boost Price Target | Canaccord Genuity | Buy | $34.00 to $51.00 |
| 2014-01-22 | Upgrade | Leerink Swann | Market Perform to Outperform | $33.00 to $45.00 |
| 2014-01-16 | Upgrade | Goldman Sachs | Sell to Neutral | |
| 2014-01-09 | Boost Price Target | Barclays | Equal Weight | $32.00 to $35.00 |
| 2013-12-02 | Boost Price Target | Barclays | Equal Weight | $30.00 to $32.00 |
| 2013-11-15 | Boost Price Target | RBC Capital | Sector Perform | $31.00 to $35.00 |
| 2013-11-15 | Boost Price Target | Needham & Company LLC | Buy | $35.00 to $40.00 |
| 2013-11-15 | Boost Price Target | Barclays | Equal Weight | $28.00 to $30.00 |
| 2013-10-30 | Reiterated | Needham | Buy | $28 to $35 |
| 2013-10-30 | Boost Price Target | RBC Capital | Sector Perform | $27.00 to $31.00 |
| 2013-10-30 | Boost Price Target | Piper Jaffray | Overweight | $31.00 to $35.00 |
| 2013-10-30 | Boost Price Target | Canaccord Genuity | Buy | $34.00 |
| 2013-10-30 | Boost Price Target | BMO Capital Markets | Market Perform | $25.00 to $28.00 |
| 2013-10-30 | Reiterated Rating | Goldman Sachs | Sell | $22.00 |
| 2013-10-30 | Boost Price Target | Barclays | Equal Weight | $23.00 to $28.00 |
| 2013-10-30 | Boost Price Target | Needham & Company LLC | Buy | $28.00 to $35.00 |
| 2013-10-14 | Downgrade | Goldman Sachs | Neutral to Sell | $25.00 to $22.00 |
| 2013-10-14 | Upgrade | BMO Capital Markets | Underperform to Market Perform | $22.00 to $25.00 |
| 2013-08-08 | Initiated | Needham | Buy | $28 |
| 2013-06-19 | Reiterated | Canaccord Genuity | Buy | $24.50 to $29 |
| 2013-05-17 | Initiated | WallachBeth | Buy | $27 |
| 2013-02-27 | Reiterated | Barclays | Equal Weight | $17 to $19 |
| 2013-02-27 | Downgrade | Mizuho | Buy to Neutral | |
| 2012-10-04 | Reiterated | Mizuho | Buy | $26 to $20 |
| 2012-10-04 | Downgrade | Summer Street Research | Buy to Neutral |
| 2016-07-13 | Upgrade | JPMorgan Chase & Co. | Neutral to Overweight | $55.00 to $74.00 |
| 2016-06-07 | Reiterated Rating | Morgan Stanley | Hold | $57.00 |
| 2016-06-07 | Reiterated Rating | Brean Capital | Buy | $58.00 to $60.00 |
| 2016-06-06 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2016-06-03 | Reiterated Rating | Piper Jaffray | Overweight | $58.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In NUVA 198 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Inc. | 6.50M |
| Vanguard Group, Inc | 5.41M |
| BlackRock Fund Advisors | 3.06M |
| THRIVENT FINANCIAL FOR LUTHERANS | 2.57M |
| JPMORGAN CHASE & CO | 2.38M |
| MACQUARIE GROUP LTD | 2.33M |
| CITADEL ADVISORS LLC | 1.95M |
| STATE STREET CORP | 1.83M |
| BlackRock Institutional Trust Company, N.A. | 1.55M |
| DIMENSIONAL FUND ADVISORS LP | 1.34M |
| Channing Capital Management, LLC | 1.25M |
| Paradice Investment Management LLC | 1.20M |
| CITIGROUP INC | 1.11M |
| GEODE CAPITAL MANAGEMENT, LLC | 0.95M |
| BANK OF AMERICA CORP /DE/ | 0.81M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Lukianov Alexis V Chairman & CEO | 0.70% (328367) | NUVA / OFIX / VOLC / |
| LUCIER GREGORY T | 0.30% (141516) | CFN / CTLT / LIFE / NUVA / |
| Valentine Keith President & COO | 0.19% (88934) | NUVA / SPNE / |
| Link Matthew Exec. VP U.S. Sales | 0.18% (86143) | NUVA / |
| BLAIR JACK R | 0.17% (80054) | NUVA / |
| Miles Patrick Pres., Global Products & Svcs | 0.15% (72756) | ATEC / NUVA / |
| Powers Russell Exec. VP Sales Int\'l Ops | 0.14% (64201) | NUVA / |
| Hannon Jason EVP, Gen. Counsel & Secretary | 0.10% (44961) | NUVA / |
| Hunsaker Craig E SVP, Global Human Resources | 0.09% (44007) | ATEC / NUVA / |
| HUNT ROBERT J | 0.07% (34500) | NUVA / |
| Blackford Quentin S. CFO and CAO | 0.04% (21078) | ATEC / DXCM / NUVA / |
| MORE EILEEN M | 0.04% (16833) | NUVA / |
| FARRELL PETER C | 0.03% (15627) | NUVA / RMD / |
| Carol Cox EVP Strategy, Corp Dev | 0.03% (14043) | NUVA / |
| Leddy Peter Michael | 0.03% (13750) | LIFE / NUVA / |
| LAMBERT MICHAEL Executive Vice Pres. & CFO | 0.03% (13631) | NUVA / |
| HOWE LESLEY H | 0.02% (10997) | JMBA / NUVA / VOLC / |
| OHALLERAN MICHAEL D | 0.02% (10295) | CFN / NUVA / |
| Sylvain Jereme M Chief Accounting Officer | 0.02% (7943) | NUVA / |
| Rosenberg Donald J | 0.01% (5963) | NUVA / QCOM / |
| Rozow Stephen EVP, Global Process | 0.01% (4075) | NUVA / |
| Paolucci Michael E Exec. V.P., Global HR | 0.01% (3000) | CFN / NUVA / OFIX / |
UM